Targeted Molecular Profiling of Non-small Cell Lung Cancer in India
Open Access
- 17 March 2024
- journal article
- Published by Brieflands in Journal of Advanced Immunopharmacology
- Vol. 4 (1)
Abstract
: Cancer often rates highly on lists of the world's most hazardous diseases and routinely appears high on lists of the illnesses that people fear the most. Due of its relevance to the subject at hand, this article concentrates on lung cancer rather than other forms of malignancy. Most patients, both those who have never smoked cigarette as well as those who have, are affected by NSCLC, the more common of these two types. The Mesenchymal – Epithelial Transition (MET) protein amplification, EGFR mutations, RET fusions, and other possible therapeutic targets for the treatment of non-small cell lung cancer are highlighted in this article. The primary aim of this article is to provide a gist of the various mutations and targets' modes of action. It also covers the limits of the medicines that are currently being used to treat certain targets.Keywords
This publication has 103 references indexed in Scilit:
- SY20-1 Novel agents for KRAS-mutant NSCLCAnnals of Oncology, 2022
- A review of NTRK fusions in cancerAnnals of Medicine & Surgery, 2022
- PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progressionCancer Immunology, Immunotherapy, 2022
- Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancersActa Pharmaceutica Sinica B, 2021
- Advances in anti-BRAF therapies for lung cancerInvestigational New Drugs, 2021
- Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerAnnals of Oncology, 2020
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerAnnals of Oncology, 2020
- The METeoric rise of MET in lung cancerCancer, 2020
- Induction of apoptosis by morusin in human non-small cell lung cancer cells by suppression of EGFR/STAT3 activationBiochemical and Biophysical Research Communications, 2018
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerJAMA Oncology, 2016